173 related articles for article (PubMed ID: 21848694)
1. The Syk-kinase inhibitor R406 impairs platelet activation and monocyte tissue factor expression triggered by heparin-PF4 complex directed antibodies.
Lhermusier T; van Rottem J; Garcia C; Xuereb JM; Ragab A; Martin V; Gratacap MP; Sié P; Payrastre B
J Thromb Haemost; 2011 Oct; 9(10):2067-76. PubMed ID: 21848694
[TBL] [Abstract][Full Text] [Related]
2. The novel Syk inhibitor R406 reveals mechanistic differences in the initiation of GPVI and CLEC-2 signaling in platelets.
Spalton JC; Mori J; Pollitt AY; Hughes CE; Eble JA; Watson SP
J Thromb Haemost; 2009 Jul; 7(7):1192-9. PubMed ID: 19422460
[TBL] [Abstract][Full Text] [Related]
3. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation.
Braselmann S; Taylor V; Zhao H; Wang S; Sylvain C; Baluom M; Qu K; Herlaar E; Lau A; Young C; Wong BR; Lovell S; Sun T; Park G; Argade A; Jurcevic S; Pine P; Singh R; Grossbard EB; Payan DG; Masuda ES
J Pharmacol Exp Ther; 2006 Dec; 319(3):998-1008. PubMed ID: 16946104
[TBL] [Abstract][Full Text] [Related]
4. PRT-060318, a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model.
Reilly MP; Sinha U; André P; Taylor SM; Pak Y; Deguzman FR; Nanda N; Pandey A; Stolla M; Bergmeier W; McKenzie SE
Blood; 2011 Feb; 117(7):2241-6. PubMed ID: 21088136
[TBL] [Abstract][Full Text] [Related]
5. TULA-2 (T-Cell Ubiquitin Ligand-2) Inhibits the Platelet Fc Receptor for IgG IIA (FcγRIIA) Signaling Pathway and Heparin-Induced Thrombocytopenia in Mice.
Zhou Y; Abraham S; Renna S; Edelstein LC; Dangelmaier CA; Tsygankov AY; Kunapuli SP; Bray PF; McKenzie SE
Arterioscler Thromb Vasc Biol; 2016 Dec; 36(12):2315-2323. PubMed ID: 27765766
[TBL] [Abstract][Full Text] [Related]
6. A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes.
Cha HS; Boyle DL; Inoue T; Schoot R; Tak PP; Pine P; Firestein GS
J Pharmacol Exp Ther; 2006 May; 317(2):571-8. PubMed ID: 16452391
[TBL] [Abstract][Full Text] [Related]
7. B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406.
Quiroga MP; Balakrishnan K; Kurtova AV; Sivina M; Keating MJ; Wierda WG; Gandhi V; Burger JA
Blood; 2009 Jul; 114(5):1029-37. PubMed ID: 19491390
[TBL] [Abstract][Full Text] [Related]
8. Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia.
Pouplard C; Iochmann S; Renard B; Herault O; Colombat P; Amiral J; Gruel Y
Blood; 2001 May; 97(10):3300-2. PubMed ID: 11342462
[TBL] [Abstract][Full Text] [Related]
9. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia.
Buchner M; Baer C; Prinz G; Dierks C; Burger M; Zenz T; Stilgenbauer S; Jumaa H; Veelken H; Zirlik K
Blood; 2010 Jun; 115(22):4497-506. PubMed ID: 20335218
[TBL] [Abstract][Full Text] [Related]
10. Polymorphisms of protein tyrosine phosphatase CD148 influence FcγRIIA-dependent platelet activation and the risk of heparin-induced thrombocytopenia.
Rollin J; Pouplard C; Gratacap MP; Leroux D; May MA; Aupart M; Gouilleux-Gruart V; Payrastre B; Gruel Y
Blood; 2012 Aug; 120(6):1309-16. PubMed ID: 22677127
[TBL] [Abstract][Full Text] [Related]
11. Spleen tyrosine kinase (Syk) inhibitor fostamatinib limits tissue damage and fibrosis in a bleomycin-induced scleroderma mouse model.
Pamuk ON; Can G; Ayvaz S; Karaca T; Pamuk GE; Demirtas S; Tsokos GC
Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S15-22. PubMed ID: 26148346
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and efficacy of the spleen tyrosine kinase inhibitor r406 after ocular delivery for retinoblastoma.
Pritchard EM; Stewart E; Zhu F; Bradley C; Griffiths L; Yang L; Suryadevara PK; Zhang J; Freeman BB; Guy RK; Dyer MA
Pharm Res; 2014 Nov; 31(11):3060-72. PubMed ID: 24906597
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the anti-allergic activity of Syk inhibitors with optimized Syk siRNAs in FcepsilonRI-activated RBL-2H3 basophilic cells.
Sanderson MP; Gelling SJ; Rippmann JF; Schnapp A
Cell Immunol; 2010; 262(1):28-34. PubMed ID: 20053395
[TBL] [Abstract][Full Text] [Related]
14. Deregulated Syk inhibits differentiation and induces growth factor-independent proliferation of pre-B cells.
Wossning T; Herzog S; Köhler F; Meixlsperger S; Kulathu Y; Mittler G; Abe A; Fuchs U; Borkhardt A; Jumaa H
J Exp Med; 2006 Dec; 203(13):2829-40. PubMed ID: 17130299
[TBL] [Abstract][Full Text] [Related]
15. Platelet transactivation by monocytes promotes thrombosis in heparin-induced thrombocytopenia.
Tutwiler V; Madeeva D; Ahn HS; Andrianova I; Hayes V; Zheng XL; Cines DB; McKenzie SE; Poncz M; Rauova L
Blood; 2016 Jan; 127(4):464-72. PubMed ID: 26518435
[TBL] [Abstract][Full Text] [Related]
16. Streptococcus sanguis-induced platelet activation involves two waves of tyrosine phosphorylation mediated by FcgammaRIIA and alphaIIbbeta3.
Pampolina C; McNicol A
Thromb Haemost; 2005 May; 93(5):932-9. PubMed ID: 15886812
[TBL] [Abstract][Full Text] [Related]
17. Assessment of the effects of Syk and BTK inhibitors on GPVI-mediated platelet signaling and function.
Zheng TJ; Lofurno ER; Melrose AR; Lakshmanan HHS; Pang J; Phillips KG; Fallon ME; Kohs TCL; Ngo ATP; Shatzel JJ; Hinds MT; McCarty OJT; Aslan JE
Am J Physiol Cell Physiol; 2021 May; 320(5):C902-C915. PubMed ID: 33689480
[TBL] [Abstract][Full Text] [Related]
18. Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor.
Pine PR; Chang B; Schoettler N; Banquerigo ML; Wang S; Lau A; Zhao F; Grossbard EB; Payan DG; Brahn E
Clin Immunol; 2007 Sep; 124(3):244-57. PubMed ID: 17537677
[TBL] [Abstract][Full Text] [Related]
19. Measurement of procoagulant platelets provides mechanistic insight and diagnostic potential in heparin-induced thrombocytopenia.
Lee CSM; Selvadurai MV; Pasalic L; Yeung J; Konda M; Kershaw GW; Favaloro EJ; Chen VM
J Thromb Haemost; 2022 Apr; 20(4):975-988. PubMed ID: 35038779
[TBL] [Abstract][Full Text] [Related]
20. PF4/heparin-antibody complex induces monocyte tissue factor expression and release of tissue factor positive microparticles by activation of FcγRI.
Kasthuri RS; Glover SL; Jonas W; McEachron T; Pawlinski R; Arepally GM; Key NS; Mackman N
Blood; 2012 May; 119(22):5285-93. PubMed ID: 22394597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
